


FY 2017

Cumulative Performance since 2010

✓ Number of Contracts



✓ Target Indications and Status

NO.	Target Indications	Status	Approval Status
1	Pulmonary arterial hypertension	Ongoing	Approved in 2017
2	Pediatric neurogenic detrusor overactivity (2 trials)	Ongoing	-
3	Giant congenital melanocytic nevi (Investigator-initiated)	Completed	Approved in 2016
4	Attention deficit hyperactivity disorder (2 trials)	Completed	Approved in 2017
5	Noonan syndrome	Ongoing	Approved in 2017
6	Down syndrome	Terminated	-
7	Juvenile idiopathic arthritis	Ongoing	Approved in 2018
8	Pulmonary arterial hypertension	Ongoing	-
9	Infantile hemangioma	Completed	Approved in 2016
10	Gastrointestinal Diseases	Completed	Approved in 2017
11	Haemophilia A	Ongoing	-
12	Haemophilia B	Ongoing	-
13	Thrombosis(2 trials)	Ongoing	-
14	Status epilepticus	Completed	-
15	Systemic juvenile idiopathic arthritis	Ongoing	-
16	Growth hormone deficiency (2 trials)	Terminated	-
17	Hypertension(2 trials)	Ongoing(1 trial)	-
18	Haemophilia A	Completed	-
19	Patent ductus arteriosus	Completed	Approved in 2017
20	Retinopathy of prematurity (2 trials)	Ongoing	-
21	Respiratory syncytial virus infection	Ongoing	-
22	Type 1 diabetes mellitus	Ongoing	-
23	Growth hormone deficiency	Ongoing	-
24	Pediatric subjects in the intensive care unit	Completed	-
25	Haemophilia A	Completed	-
26	Heart failure	Ongoing	-
27	Growth hormone deficiency	Ongoing	-
28	Pediatric epilepsy	Ongoing	-
29	Spinal Muscular Atrophy (2 trials)	Ongoing	-
30	Status epilepticus (2 trials)	Ongoing	-
31	Heart failure	Ongoing	-
32	Ulcerative colitis(2 trials)	Ongoing	-
33	Cancer pain	Ongoing	-
34	Glioma	Ongoing	-


✓ Ongoing: 29 trials

✓ Completed: 11 trials

✓ Terminated: 3 trials

✓ Approved for marketing: 8 trials

✓ Clinical department



Distribution of the clinical trial by clinical department

✓ Number of Feasibility Surveys

